---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044572"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:34:20.087092+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enveric out-licenses EB-002 to MycoMedica for up to $62M milestones plus royalties

## Summary
- Exclusive global license for EB-002 (EVM201) to treat neuropsychiatric disorders.
- Enveric receives modest upfront payments; eligible for up to $62M in development/sales milestones.
- Tiered single-digit royalties on all future sales; MycoMedica has buyout options.
- Enveric will focus resources on lead candidate EB-003, targeting IND filing in 2025.
- MycoMedica assumes all future preclinical, clinical, and commercial development costs.

## SEC filing metadata
- accession: 0001493152-24-044572
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224044572/0001493152-24-044572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224044572/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044572
- JSON: https://secwatch.observer/filing/0001493152-24-044572.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.